Sichuan Defeng Pharmaceutical Co., Ltd.

Main purpose: To examine the relationship between emestine fumarate sustained-release capsules (test preparation T, specification: 2 mg) produced by Sichuan Defeng Pharmaceutical Co., Ltd. and fumarate produced by Xinghe Co., Ltd. in the fasting/postprandial state. Pharmacokinetic characteristics of emestine acid sustained-release capsules (reference preparation R, trade name: REMICUT®, strength: 2 mg) in healthy Chinese adult subjects, and evaluation of the two preparations administered on an empty stomach and after meals Bioequivalence under conditions. Secondary purpose: To observe the safety of the test formulation emedestine fumarate sustained-release capsules and the reference formulation emedestine fumarate sustained-release capsules (REMICUT®) in healthy adult subjects in China.

"Main research purpose: According to the regulations on bioequivalence testing, select emestine fumarate sustained-release capsules (trade name: REMICUT; specification: 2 mg) of Japan Kowa Co., Ltd. as the licensee as the reference preparation , conduct human bioequivalence tests on fasting and postprandial administration of the test preparation emestine fumarate sustained-release capsules (specification: 2 mg) produced and provided by Sichuan Defeng Pharmaceutical Co., Ltd., and compare the drugs in the test preparation Whether the difference in absorption rate and degree of absorption from the reference preparation is within the acceptable range, evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary research purpose: To observe Chinese healthy subjects taking the test preparation emedestine fumarate sustained-release capsules (specification: 2 mg) and the reference preparation emedestine fumarate sustained-release capsules (trade name: REMICUT; Specification: 2mg) after safety.